Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement
| Autor: | Francesco Giotta, Agnese Latorre, Antonio Cramarossa, Giovanni Simone, Carlo Florio, Stefano Oliva, Vito Lorusso |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
0301 basic medicine
Cancer Research Receptor ErbB-2 Breast Neoplasms Antibodies Monoclonal Humanized Vinblastine Deoxycytidine Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans skin and connective tissue diseases neoplasms Capecitabine Liver Neoplasms Lapatinib Vinorelbine General Medicine Middle Aged Trastuzumab Immunohistochemistry Up-Regulation 030104 developmental biology Treatment Outcome Oncology Receptors Estrogen Chemotherapy Adjuvant 030220 oncology & carcinogenesis Quinazolines Female Fluorouracil Receptors Progesterone Tomography X-Ray Computed |
| Zdroj: | Tumori. 99(6) |
| ISSN: | 2038-2529 |
| Popis: | We present the case of a 58-year-old woman with breast cancer metastasizing to the liver after adjuvant chemotherapy. A liver biopsy confirmed metastatic lesions from breast cancer that were immunohistochemically positive for estrogen/progesterone receptors and HER2. After first-line treatment with trastuzumab and vinorelbine, the patient commenced therapy with capecitabine (1000 mg/m2 twice daily, days 1–14) and lapatinib (1250 mg/day). Three months after the administration of this combination therapy, the liver metastases had shrunk substantially. Lapatinib may have the potential to convert trastuzumab-refractory tumors to trastuzumab-sensitive tumors in HER2-positive breast cancer by upregulation of the cell surface expression of HER2. Further study will be needed to evaluate in the clinic the combination of lapatinib and an m-TOR inhibitor as a treatment approach in HER2 overexpressing breast cancer that shows a poor response to trastuzumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|